AEMD: Rata-rata rega prakiraan Aethlon

Patents and FDA recognition of the innovative nature of plasma purification systems ensure a high barrier to entry for Aethlon Medical (AEMD). This chart reflects an asset value of 13.29. The price action is driven by the scaling of filter trials and the pursuit of government grants. Growth potential is based on the development of the Hemopurifier for the removal of tumor markers and viruses, cementing the company's role as a technological leader in precision medicine.

The consensus forecast aggregates expert fair value estimates, transforming fundamental market expectations into a single price benchmark to minimize "value trap" risks. The current consensus target reflects the probability of the Hemopurifier platform's commercial success in infection therapy, allowing investors to correlate the clinical progress of Aethlon Medical (AEMD) with an objective market revaluation of capital.